摘要
横纹肌肉瘤(RMS)是最常见的儿童软组织肿瘤,约占儿童恶性肿瘤的7%。标准治疗横纹肌肉瘤的多模式疗法一般不能治愈高风险组患者,并可能导致长期的副作用。因此,了解导致RMS的机制可能有助于找到新的、更具体和有效的治疗方法。导致肿瘤产生的一种分子机制是Hedgehog (Hh)信号途径。有越来越多的证据表明,Hedgehog (Hh)信号途径可能是治疗RMS的新方法。本文讨论了Hedgehog通路在治疗RMS的作用、在儿童中抑制这种胚胎信号的挑战以及正在进行的临床试验。
关键词: 小儿肿瘤、横纹肌肉瘤、发展途径、Hedgehog信号通路,小鼠模型,靶向治疗。
图形摘要
Current Drug Targets
Title:Interfering with Hedgehog Pathway: New Avenues for Targeted Therapy in Rhabdomyosarcoma
Volume: 17 Issue: 11
Author(s): Gabriele Manzella and Beat W. Schäfer
Affiliation:
关键词: 小儿肿瘤、横纹肌肉瘤、发展途径、Hedgehog信号通路,小鼠模型,靶向治疗。
摘要: Rhabdomyosarcoma (RMS) is the most frequent pediatric soft-tissue tumor accounting for about 7% of childhood malignancies. Multimodal therapy is the standard treatment for individuals with RMS but generally fails to cure high-risk group patients and can result in long-term side effects. Therefore, understanding the mechanisms driving RMS might help to find new candidate targets for more specific and effective therapeutic modalities. One of the molecular machineries which is often deregulated in cancer and specifically involved in tumorigenesis of RMS, is Hedgehog (Hh) signaling. There is increasing evidence that targeting this developmental pathway may hold promise in future treatment strategies for RMS. In this review, we discuss the contribution of the Hh pathway in RMS, the challenges of inhibiting this embryonic signaling in children with an update on recent preclinical data and ongoing clinical trials.
Export Options
About this article
Cite this article as:
Gabriele Manzella and Beat W. Schäfer , Interfering with Hedgehog Pathway: New Avenues for Targeted Therapy in Rhabdomyosarcoma, Current Drug Targets 2016; 17 (11) . https://dx.doi.org/10.2174/1389450116666150505122604
DOI https://dx.doi.org/10.2174/1389450116666150505122604 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hypoxia-Inducible Factor-1 (HIF-1): A Potential Target for Intervention in Ocular Neovascular Diseases
Current Drug Targets Delivery Systems for Birch-bark Triterpenoids and their Derivatives in Anticancer Research
Current Medicinal Chemistry Effects of Diet-Derived Molecules on the Tumor Microenvironment
Current Angiogenesis (Discontinued) Pixuvri<sup>®</sup> (Pixantrone Dimaleate, BBR 2778): From Lab to Market
Current Organic Chemistry Recent Advances in Anti-Survivin Treatments for Cancer
Current Medicinal Chemistry Recent Advances in the Therapeutic Perspectives of Nutlin-3
Current Pharmaceutical Design miRNAs Highlights in Stem and Cancer Cells
Mini-Reviews in Medicinal Chemistry BUB1B Promotes Proliferation of Prostate Cancer via Transcriptional Regulation of MELK
Anti-Cancer Agents in Medicinal Chemistry Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling
Current Drug Targets 1,3,4-Thiadiazole Based Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry CXCR4-CXCL12-Dependent Inflammatory Network and Endothelial Progenitors
Current Medicinal Chemistry Cause and Consequences of Genetic and Epigenetic Alterations in Human Cancer
Current Genomics Network-Based Strategies Can Help Mono- and Poly-pharmacology Drug Discovery: A Systems Biology View
Current Pharmaceutical Design IP6 & Inositol in Cancer Prevention and Therapy
Current Cancer Therapy Reviews Antiproliferative and Proapoptotic Effects of the TrK-inhibitor GW441756 in Human Myosarcomas and Prostatic Carcinoma
Current Signal Transduction Therapy An Expanding Appreciation of the Role Chemokine Receptors Play in Cancer Progression
Current Pharmaceutical Design Circadian Timekeeping in Anticancer Therapeutics: An Emerging Vista of Chronopharmacology Research
Current Drug Metabolism Fibroblast Growth Factor Receptor Inhibitors
Current Pharmaceutical Design CD95 Signaling in Cancer Treatment
Current Pharmaceutical Design WT1 Peptide Vaccine as a Paradigm for “Cancer Antigen-Derived Peptide”-Based Immunotherapy for Malignancies: Successful Induction of Anti-Cancer Effect by Vaccination with a Single Kind of WT1 Peptide
Anti-Cancer Agents in Medicinal Chemistry